New stock news | UK biopharmaceutical company Allergy Therapeutics considers listing in Hong Kong.

UK-based biopharmaceutical company Allergy Therapeutics, listed on the AIM market, announced on November 6th that they are in the process of evaluating the possibility of a dual listing on the main board of the Hong Kong Stock Exchange. If they decide to proceed, the company plans to complete the listing in the first half of 2026. The company emphasized that the listing application on HKEX would need to be approved by HKEX and the Hong Kong Securities and Futures Commission. Allergy Therapeutics stated that the Hong Kong listing (while maintaining their AIM listing) reflects their vision to expand their business footprint in Asia, aiming to become a leader in the global allergy treatment field. The HKEX listing and related equity issuance would broaden the company's investor base to include investors from Hong Kong and mainland China, aligning with the company's growth objectives in the region. The dual listing will enhance the liquidity of their ordinary shares. Allergy Therapeutics, headquartered in the UK, is a British biotechnology company focused on allergy immunotherapy.